Abstract 55P
Background
Metastasectomy of liver metastases of colorectal cancer (CRC) offers the greatest likelihood of cure. Nevertheless, recurrence rates after this procedure are high, and chemotherapy is a reasonable choice with inconclusive evidence. In our study, we aimed to investigate the parameters that can be used to predict the development of recurrence after metastasectomy by examining clinical, pathological and molecular markers in primary tumor and their liver metastases.
Methods
Epithelial-mesenchymal-Transition (EMT) mechanism, cancer stem cell markers (CSC) and RAS, mTOR, CMYC pathways were examined in primary CRC tissues and meastatic tissues of 84 patients.
Results
Recurrence occurred after metastasectomy in 40.5% of patients. While no difference was found between the development of recurrence and tumor localization, age, and pathological data, a significant relationship was found between gender and adjuvant treatment and recurrence. The chemotherapy regimens were as follows: capecitabine plus oxaliplatin (XELOX) in 12 patients; fluorouracil, leucovorin, and irinotecan (FOLFIRI) in 20 patients; fluorouracil, leucovorin, and oxaliplatin (FOLFOX-6) in 11 patients. Seventeen patients received neadjuvant therapy and 26 patients received adjuvant therapy. All patients received 5fu-based chemotherapy. Snail and mTOR showed a statistically significant increase in the metastatic tumor tissues of patients with recurrence (P= 0.001, P=0.015; respectively).
Conclusions
Results showed that the Sanil and mTOR expression levels could be a clinically relevant predictive indicator of remnant liver recurrence. In these patients with liver metastases, the use of mTOR inhibitors may be considered after hepatic metastasectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S. Aksoy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.